Glenmark将在2026年3月推出通用的Potassium Phoosphates注射,为医院提供负担得起的生物等值选择。 Glenmark to launch generic Potassium Phosphates Injection in March 2026, offering affordable, bioequivalent options for hospitals.

Glennmark制药公司美国分公司计划在2026年3月推出其通用的Potassium Phoosphates注射USP, 提供5毫升、15毫升和50毫升配方生物等效于Fresenius Kabi的参考药物。 Glenmark Pharmaceuticals Inc USA plans to launch its generic Potassium Phosphates Injection USP in March 2026, offering 5 mL, 15 mL, and 50 mL formulations bioequivalent to Fresenius Kabi’s reference drug. 该产品用于治疗磷酸盐缺乏症,预计能以可靠、负担得起的办法支持医院的配方。 The product, used to treat phosphate deficiencies, is expected to support hospital formularies with a reliable, affordable option. 美国的毒品销售额在2026年1月截止的12个月中达到5 070万美元左右。 U.S. sales for the drug reached about $50.7 million over the 12 months ending January 2026. 该发射扩大了Glenmark提供的机构渠道,并体现了其对可获得的注射治疗的承诺。 The launch expands Glenmark’s institutional channel offerings and reflects its commitment to accessible injectable treatments.